Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Magro CM, Mulvey J, Kubiak J, Mikhail S, Suster D, A Crowson N, et al. Severe COVID-19: A multifaceted viral vasculopathy syndrome. Ann Diagn Pathol. 2021;50:151645.

Xu H, Magro C, Minkis K. Potential Masquerader of Malignancy: Tophaceous Gout Causing Nail Dystrophy. Dermatol Surg. 2021;47(8):1149-1150.

Patel A, Hoda RS, Hoda SA. Papillary Breast Tumors: Continuing Controversies and Commentary on WHO's 2019 Criteria and Classification. Int J Surg Pathol. 2021:10668969211035843.

Park HJ, Baek I, Cheang G, Solomon JP, Song W. Comparison of RNA-Based Next-Generation Sequencing Assays for the Detection of NTRK Gene Fusions. J Mol Diagn. 2021;23(11):1443-1451.

Castrodad-Rodríguez CA, Choudhuri J, El-Jabbour T, Cheng J, Westerhoff M, Panarelli NC. Clinical significance of pathologic abnormalities in biopsy samples from the appendiceal orifice. Histopathology. 2021;79(5):751-757.

Magro CM, Mulvey JJ, Laurence J, Sanders S, Crowson AN, Grossman M, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2021;184(1):141-150.

Sakunrangsit N, Pholtaisong J, Sucharitakul J, Wanna-Udom S, Prombutara P, Pisitkun P, et al. Identification of candidate regulators of mandibular bone loss in FcγRIIB Mice. Sci Rep. 2021;11(1):18726.

Butler D, Mozsary C, Meydan C, Foox J, Rosiene J, Shaiber A, et al. Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. Nat Commun. 2021;12(1):1660.

Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Winger BA, et al. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021;11(6):1424-1439.

Petroni G, Buqué A, Yamazaki T, Bloy N, Di Liberto M, Chen-Kiang S, et al. Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer. Clin Cancer Res. 2021;27(7):1855-1863.